Drug profile · INN
tagraxofusp
ELZONRIS
tagraxofusp (ELZONRIS) is a interleukin-3 receptor subunit alpha binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX67
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — tagraxofusp
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
tagraxofusp (ELZONRIS) is a interleukin-3 receptor subunit alpha binding agent.
Key facts
INN tagraxofusp
Brand ELZONRIS
Mechanism Interleukin-3 receptor subunit alpha binding agent
Target Elongation factor 2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX67
Mechanism of action
Interleukin-3 receptor subunit alpha binding agent
Primary target: Elongation factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tagraxofusp?
tagraxofusp (ELZONRIS) is a interleukin-3 receptor subunit alpha binding agent.
What is the brand name for tagraxofusp?
ELZONRIS is a marketed brand name for tagraxofusp. Check FDA Drugs@FDA for the current US label holder and prescribing information.